Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer-Reference-Cited by-同舟云学术

Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer

Published:2014-04-11 Issue:12 Volume:20 Page:3289-3298
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Gross Neil D.,Bauman Julie E.,Gooding William E.,Denq William,Thomas Sufi M.,Wang Lin,Chiosea Simion,Hood Brian L.,Flint Melanie S.,Sun Mai,Conrads Thomas P.,Ferris Robert L.,Johnson Jonas T.,Kim Seungwon,Argiris Athanassios,Wirth Lori,Nikiforova Marina N.,Siegfried Jill M.,Grandis Jennifer R.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sulindac exhibits anti-proliferative and anti-invasive effects in uterine serous carcinoma cells;Journal of Cancer Research and Clinical Oncology;2024-08-28

2. Celecoxib and sulindac sulfide elicit anticancer effects on PIK3CA-mutated head and neck cancer cells through endoplasmic reticulum stress, reactive oxygen species, and mitochondrial dysfunction;Biochemical Pharmacology;2024-06

3. Mononuclear phagocyte system-related multi-omics features yield head and neck squamous cell carcinoma subtypes with distinct overall survival, drug, and immunotherapy responses;Journal of Cancer Research and Clinical Oncology;2024-01-27

4. Teatro da PombaGira: origens e dinâmicas de criação: Douglas Ricci entrevista Marcelo D’Avilla;Sala Preta;2023-12-29

5. Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer;Cancer Research Communications;2023-08-10